TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines
Brief Summary: The purpose of this study is to investigate the use of a fourth fractional booster dose of sanofi pasteur's IMOVAX Polio injected intradermally (using the Mantoux technique) as booster dose between 15 to 18 months of age, in terms of immunogenicity and safety.

Objectives:

* To describe in each group the immunogenicity of IMOVAX Polio administered intradermally or intramuscularly, one month after the booster dose given at 15-18 months of age in toddlers previously primed with three doses of IMOVAX Polio vaccine during the IPV25 study.
* To describe in each group the safety of the booster dose of IMOVAX Polio vaccine administered intradermally or intramuscularly.


Options:
A: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group B
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group B
D: Arm Label: Sabin-IPV; Type: EXPERIMENTAL; Interventions: Drug: Sabin-IPV | Arm Label: Adjuvanted Sabin-IPV; Type: EXPERIMENTAL; Interventions: Drug: Adjuvanted Sabin-IPV | Arm Label: IPV; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPV | Intervention Type: DRUG; Name: IPV; Assigned to Arm(s): IPV | Intervention Type: DRUG; Name: Sabin-IPV; Assigned to Arm(s): Sabin-IPV | Intervention Type: DRUG; Name: Adjuvanted Sabin-IPV; Assigned to Arm(s): Adjuvanted Sabin-IPV

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Efficacy and Tolerability of Docosahexaenoic Acid (DHA) on Children Affected by Nonalcoholic Fatty Liver Disease (NAFLD).
Brief Summary: The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease (NAFLD).


Options:
A: Arm Label: Prebiotic Fibre; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotic fibre, Behavioral: Weight Loss | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo, Behavioral: Weight Loss | Arm Label: Weight Loss; Type: OTHER; Interventions: Behavioral: Weight Loss | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic fibre; Assigned to Arm(s): Prebiotic Fibre | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Weight Loss; Assigned to Arm(s): Placebo, Prebiotic Fibre, Weight Loss
B: Arm Label: caffeine and chlorogeinc acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine and chlorogenic acid | Arm Label: caffeine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine | Arm Label: chlorogenic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: chlorogenic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine and chlorogenic acid; Assigned to Arm(s): caffeine and chlorogeinc acid | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine; Assigned to Arm(s): caffeine | Intervention Type: DIETARY_SUPPLEMENT; Name: chlorogenic acid; Assigned to Arm(s): chlorogenic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: DHA250; Type: EXPERIMENTAL; Interventions: Drug: DHA250, Behavioral: Lifestyle intervention | Arm Label: DHA500; Type: EXPERIMENTAL; Interventions: Drug: DHA500, Behavioral: Lifestyle intervention | Arm Label: PLA; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO, Behavioral: Lifestyle intervention | Intervention Type: DRUG; Name: DHA250; Assigned to Arm(s): DHA250 | Intervention Type: DRUG; Name: DHA500; Assigned to Arm(s): DHA500 | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLA | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): DHA250, DHA500, PLA
D: Arm Label: VSL#3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: VSL#3 placebo | Arm Label: VSL#3 active probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 active probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 active probiotic; Assigned to Arm(s): VSL#3 active probiotic | Intervention Type: OTHER; Name: VSL#3 placebo; Assigned to Arm(s): VSL#3 placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa
Brief Summary: The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare the safety in participants with cystic fibrosis and chronic infection of the lungs with Pseudomonas aeruginosa.


Options:
A: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
B: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
C: Arm Label: 32.50 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: 48.75 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: Matching Placebo for 32.50 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Matching Placebo for 48.75 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 32.50 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 32.50 mg | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 48.75 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 48.75 mg
D: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa
Brief Summary: The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare the safety in participants with cystic fibrosis and chronic infection of the lungs with Pseudomonas aeruginosa.


Options:
A: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
B: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A
C: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
D: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa
Brief Summary: The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare the safety in participants with cystic fibrosis and chronic infection of the lungs with Pseudomonas aeruginosa.


Options:
A: Arm Label: Aeroquin 240 mg; Type: EXPERIMENTAL; Interventions: Drug: Aeroquin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aeroquin; Assigned to Arm(s): Aeroquin 240 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
C: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)
D: Arm Label: Observational; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa
Brief Summary: The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare the safety in participants with cystic fibrosis and chronic infection of the lungs with Pseudomonas aeruginosa.


Options:
A: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A
B: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
C: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
D: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Before and After Study of the Impact of Lower Chloride Intravenous Fluid Management on Patients' Acid-base Status, Renal Profile,Length of Stay and Mortality.
Brief Summary: The purpose of this study is to determine whether intravenous fluid management using lower chloride solutions (Hartmann's solutions and Plasmalyte®) will result in better outcome when compared to management using high chloride solutions (0.9% saline and Gelofusine®).


Options:
A: Arm Label: Lactated ringers solution; Type: EXPERIMENTAL; Interventions: Drug: Lactated Ringer Solution | Arm Label: Normal saline solution; Type: EXPERIMENTAL; Interventions: Drug: Normal Saline 0.9% Infusion Solution Bag | Intervention Type: DRUG; Name: Lactated Ringer Solution; Assigned to Arm(s): Lactated ringers solution | Intervention Type: DRUG; Name: Normal Saline 0.9% Infusion Solution Bag; Assigned to Arm(s): Normal saline solution
B: Arm Label: Plasma-Lyte, Slow Infusion; Type: EXPERIMENTAL; Interventions: Drug: Plasma-Lyte, Other: Slow infusion speed | Arm Label: Plasma-Lyte, Fast Infusion; Type: EXPERIMENTAL; Interventions: Drug: Plasma-Lyte, Other: Fast Infusion Speed | Arm Label: Saline 0.9%, Slow Infusion; Type: EXPERIMENTAL; Interventions: Drug: Saline 0.9%, Other: Slow infusion speed | Arm Label: Saline 0.9%, Fast Infusion; Type: EXPERIMENTAL; Interventions: Drug: Saline 0.9%, Other: Fast Infusion Speed | Intervention Type: DRUG; Name: Plasma-Lyte; Assigned to Arm(s): Plasma-Lyte, Fast Infusion, Plasma-Lyte, Slow Infusion | Intervention Type: DRUG; Name: Saline 0.9%; Assigned to Arm(s): Saline 0.9%, Fast Infusion, Saline 0.9%, Slow Infusion | Intervention Type: OTHER; Name: Slow infusion speed; Assigned to Arm(s): Plasma-Lyte, Slow Infusion, Saline 0.9%, Slow Infusion | Intervention Type: OTHER; Name: Fast Infusion Speed; Assigned to Arm(s): Plasma-Lyte, Fast Infusion, Saline 0.9%, Fast Infusion
C: Arm Label: Intravenous fluids; Type: OTHER; Interventions: Drug: Lower chloride fluids (Hartmann's solution and Plasmalyte®) | Intervention Type: DRUG; Name: Lower chloride fluids (Hartmann's solution and Plasmalyte®); Assigned to Arm(s): Intravenous fluids
D: Arm Label: 0.9% sodium chloride; Type: ACTIVE_COMPARATOR; Interventions: Other: 0.9% sodium chloride | Arm Label: Physiologically balanced fluid; Type: ACTIVE_COMPARATOR; Interventions: Other: Physiologically balanced fluid | Intervention Type: OTHER; Name: 0.9% sodium chloride; Assigned to Arm(s): 0.9% sodium chloride | Intervention Type: OTHER; Name: Physiologically balanced fluid; Assigned to Arm(s): Physiologically balanced fluid

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke: A Multi-site RCT
Brief Summary: The objective of the Program of Rehabilitative Exercise and Education to avert Vascular Events after Non-disabling stroke and Transient ischemic attack (PREVENT) Trial is to determine whether the timely delivery of secondary stroke prevention strategies will reduce modifiable vascular risk factors in two groups of people who have survived NDS or TIA. One group will receive a comprehensive education and exercise program (PREVENT); the other group will receive usual care (USUAL CARE). We will measure modifiable vascular risk factors in both groups. We will also compare the effects of PREVENT vs USUAL CARE on exercise capacity, walking endurance, and daily physical activity. In addition, we will compare thinking ability, depression, achievement of personal goals for healthy behavior, and health-related goal attainment and health-related quality of life. Finally, we will compare outcomes in urban and rural settings as well as costs of the PREVENT program and USUAL CARE in order to assess sustainability of the PREVENT program.


Options:
A: Arm Label: Nursing educational intervention; Type: EXPERIMENTAL; Interventions: Other: Nursing educational intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nursing educational intervention; Assigned to Arm(s): Nursing educational intervention
B: Arm Label: PREVENT program; Type: EXPERIMENTAL; Interventions: Behavioral: PREVENT program | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: PREVENT program; Assigned to Arm(s): PREVENT program | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Standard Care, Organized Discharge; Type: PLACEBO_COMPARATOR; Interventions: Other: Video Arm | Arm Label: Video Arm, Standard Discharge; Type: EXPERIMENTAL; Interventions: Other: Video Arm | Intervention Type: OTHER; Name: Video Arm; Assigned to Arm(s): Standard Care, Organized Discharge, Video Arm, Standard Discharge
D: Arm Label: Talking Rx; Type: EXPERIMENTAL; Interventions: Behavioral: Talking Rx | Arm Label: Usual Care, Prescriptions and Counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Talking Rx; Assigned to Arm(s): Talking Rx

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke: A Multi-site RCT
Brief Summary: The objective of the Program of Rehabilitative Exercise and Education to avert Vascular Events after Non-disabling stroke and Transient ischemic attack (PREVENT) Trial is to determine whether the timely delivery of secondary stroke prevention strategies will reduce modifiable vascular risk factors in two groups of people who have survived NDS or TIA. One group will receive a comprehensive education and exercise program (PREVENT); the other group will receive usual care (USUAL CARE). We will measure modifiable vascular risk factors in both groups. We will also compare the effects of PREVENT vs USUAL CARE on exercise capacity, walking endurance, and daily physical activity. In addition, we will compare thinking ability, depression, achievement of personal goals for healthy behavior, and health-related goal attainment and health-related quality of life. Finally, we will compare outcomes in urban and rural settings as well as costs of the PREVENT program and USUAL CARE in order to assess sustainability of the PREVENT program.


Options:
A: Arm Label: PREVENT program; Type: EXPERIMENTAL; Interventions: Behavioral: PREVENT program | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: PREVENT program; Assigned to Arm(s): PREVENT program | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Sitting; Type: EXPERIMENTAL; Interventions: Behavioral: Sitting | Arm Label: Standing; Type: EXPERIMENTAL; Interventions: Behavioral: Standing | Arm Label: Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Walking | Intervention Type: BEHAVIORAL; Name: Sitting; Assigned to Arm(s): Sitting | Intervention Type: BEHAVIORAL; Name: Standing; Assigned to Arm(s): Standing | Intervention Type: BEHAVIORAL; Name: Walking; Assigned to Arm(s): Walking
C: Arm Label: ICoreDIST; Type: EXPERIMENTAL; Interventions: Procedure: ICoreDIST | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Intervention Type: PROCEDURE; Name: ICoreDIST; Assigned to Arm(s): ICoreDIST | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard Care
D: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: A